Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time.
Jetty A OverbeekJosephina G KuiperMarina BakkerBartholomeus J F van den BemtRon M C HeringsPublished in: British journal of clinical pharmacology (2021)
The results of this large population-based cohort show an increase in biosimilar initiation in daily clinical practice. The number of switchers remains relatively low as nonmedical switch is not encouraged in the Netherlands.